Skip to content
Company Analysis

AbbVie Inc. ABBV

A comprehensive view of key metrics, scores, and financial health for AbbVie Inc.

Overview of AbbVie Inc.

ABBV NYQ
Healthcare Drug Manufacturers - General Framework: Pharma / Mature Biotech Mega Cap
AbbVie Inc. (ABBV), is a Mega Cap company, in the Drug Manufacturers - General industry, last closed at $288.84, about 74.2% overvalued vs fair value, +31.9% 1Y return, ranked 458/1145 in sector.
Metrics P/E 95.9× Rev Growth 8.6% ROE 15367.3% Gross Margin 70.2% Div Yield 2.89%
USD 288.84
-2.05%
(Delayed)
• Vol 90d: 23.2%
52-Week Range
Market Cap
$510.41B
Enterprise Value
$574.71B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Fair
Health
Weak
Efficiency
Weak
Valuation
Good
Growth
Fair
Profitability
Fair
Health
Weak
Efficiency
Weak
Valuation
Good
Completeness: 100%
Confidence: 97%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.abbvie.com
HQ North Chicago, IL
Employees 57,000
Fiscal year Dec 31

Next Events

Dividend Nov 16 Ex-div: Jan 15

Fair Value Snapshot

Bear Base Bull
$68
$74
$82
Current: $288.84 -74% vs base

Engine Room Money Flow™

Mega Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$61.2B
8.6%%
Gross Profit
$43.0B
8.9%%
R&D Expense
$9.1B
-28.9%%
Operating Income (EBIT)
$9.5B
45.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
200.5%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$12.6B
70.9% of FCF

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
3
Active Leaks
0/3
Improving
1
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating AbbVie Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
46
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Cash Generation Consistent Cash generation is consistent (score 0.89), indicating reliable business model.
  • Consistent Cash Generation Cash generation is strong and consistent (score 0.89).

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.28), raising refinancing risk.
  • Liquidity Concerns Liquidity is concerning (score 0.16), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
47
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 92% Coverage
Trade-Off Triangle Visualization A ternary plot showing ABBV's balance between Growth (28.3%), Profitability (48.3%), and Safety (23.4%). Growth 28% Safety 23% Profitability 48%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

45th percentile vs peers
46
Key Signals
Rev Growth YoY 8.6% 63p Revenue CAGR 3Y 1.8% 41p TSR 32.3% 69p EPS Growth YoY -1.2% 30p EPS CAGR 3Y -29.0% 22p
Strengths
  • Superior capital returns - 2 return metrics above peer median
  • ROIC in top 20% of peers (15.0%, 86th percentile)
  • Operating Margin in top 20% of peers (24.6%, 86th percentile)
  • FCF Margin in top 20% of peers (29.1%, 93th percentile)
Risks

No significant risks identified for this axis.

Profitability

78th percentile vs peers
78
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

37th percentile vs peers
38
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for AbbVie Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$74.49
- - -
-74.2% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000